TC BioPharm (Holdings) Stock (NASDAQ: TCBP)

Dernières nouvelles pour TC BioPharm (Holdings) (NASDAQ:TCBP) Stock

TC BioPharm (Holdings)

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings) PLC

As a result of such extension, the Share Repurchase Program will expire on December 31, 2026. The Share Repurchase Program was previously scheduled to expire on December 31, 2024.&nbsp;
The other terms of the Share Repurchase Program remain unchanged, and as of December 18, 2024, the approximate dollar value of shares that may yet be purchased under the Share Repurchase Program is $1.4 billion.

News

Buybacks

EQT Board Approves Two-year Extension To Existing Share Repurchase Program, Which Program Was Originally Announced On December 13, 2021 - Filing

Dividends

ABCB

Ameris Bancorp Increases Quarterly Dividend From $0.15 To $0.20/Share

TriplePoint Venture Growth BDC Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) (the "Company" or "TPVG"), the leading financing provider to venture growth stage companies backed by a select group of venture capital firms in technology and other high growth industries, today announced the appointment of Mike L. Wilhelms as Chief Financial Officer (CFO) of the Company, effective as of January 6, 2025. Mr. Wilhelms will also serve as CFO of TriplePoint Capital LLC (TPC), TPVG's sponsor, and as CFO of TriplePoint Private Venture Credit Inc., TriplePoint Venture Lending Fund, LLC, TriplePoint Financial LLC and TriplePoint Advisers LLC. He will be based in Menlo Park, California.

Management

TPVG

TriplePoint Venture Growth BDC Corp. Names Mike L. Wilhelms CFO, Effective As Of January 6, 2025

NYSE To Begin Delisting Proceedings Against Lion Electric Company

Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has outperformed the market over the past 5 years by 21.59% on an annualized basis producing an average annual return of 34.38%. Currently, Dell Technologies has a market capitalization of $78.92 billion. 
Buying $100 In DELL: If an investor had bought $100 of DELL stock 5 years ago, it would be worth $441.39 today based on a price of $112.67 for DELL at the time of writing.
<h3>Dell Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734556520_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

DELL

Here's How Much $100 Invested In Dell Technologies 5 Years Ago Would Be Worth Today

Offerings

The Marygold Companies, Inc. Common Stock

MGLD

Marygold Companies Files For Mixed Shelf Offering Of Up To $100M

Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) reported its Q3 earnings results on Wednesday, December 18, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Steelcase beat estimated earnings by 36.0%, reporting an EPS of $0.3 versus an estimate of $0.22.
Revenue was up $17.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.02, resulting in a 6.0% drop change in the share price the following day.
Here's a look at Steelcase's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.37</td>
<td>0.10</td>
<td>0.21</td>
<td>0.23</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.39</td>
<td>0.16</td>
<td>0.23</td>
<td>0.30</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>864.10M</td>
<td>729.12M</td>
<td>780.25M</td>
<td>798.65M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>855.80M</td>
<td>727.30M</td>
<td>775.20M</td>
<td>777.90M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Steelcase <a href="https://www.benzinga.com/quote/SCS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Summary: Steelcase Q3

Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) has outperformed the market over the past 20 years by 14.16% on an annualized basis producing an average annual return of 22.39%. Currently, Old Dominion Freight Line has a market capitalization of $40.94 billion. 
Buying $100 In ODFL: If an investor had bought $100 of ODFL stock 20 years ago, it would be worth $5,685.71 today based on a price of $191.77 for ODFL at the time of writing.
<h3>Old Dominion Freight Line's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734556514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ODFL

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

The earnings results for MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) for Q2 were made public on Wednesday, December 18, 2024 at 04:05 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
MillerKnoll beat estimated earnings by 4.0%, reporting an EPS of $0.55 versus an estimate of $0.53.
Revenue was up $20.90 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
Last quarter the company missed on EPS by $0.04 which was followed by a 14.000000000000002% drop in the share price the next day.
Here's a look at MillerKnoll's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.40</td>
<td>0.53</td>
<td>0.44</td>
<td>0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.67</td>
<td>0.45</td>
<td>0.59</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>889.30M</td>
<td>898.67M</td>
<td>909.50M</td>
<td>973.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>861.50M</td>
<td>888.90M</td>
<td>872.30M</td>
<td>949.50M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
MillerKnoll management provided guidance for Q3 2025, expecting earnings between $0.41 and $0.47 per share.
To track all earnings releases for MillerKnoll <a href="https://www.benzinga.com/quote/MLKN/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MLKN

Earnings Summary: MillerKnoll Q2

HOOD

On December 16, 2024, Robinhood Markets Appoints Christopher Payne To Board, Effective Immediately - Filing

Financial Highlights from our Fiscal Year 2024:
<ul>
<li>Net sales totaled $19.5 million in fiscal 2024 or a decrease of 19.1% compared to $24.1 million in fiscal 2023.</li>
<li>Our gross profit for the year was flat at 62% in fiscal 2024 compared to 62% in fiscal 2023.</li>
<li>Our loss from operations was $3.3 million in fiscal 2024 as compared to a loss of $22.4 million in fiscal 2023.</li>
<li>Our non-GAAP adjusted EBITDA loss from operations in fiscal 2024 was approximately $1.5 compared to our non-GAAP adjusted EBITDA from operations in fiscal 2023 of approximately $5.5. million, despite the decline in revenue. Our non-GAAP adjusted EBITDA loss for the second half of 2024 was reduced to only $0.2 million from $1.2 million in the prior year comparative period.</li>
<li>Net loss attributable to common shareholders for fiscal 2024 was approximately $7.7 million or $1.79 per share as compared to a net loss for fiscal 2023 of approximately $26.9 million, or $13.30 per share. The improvement in fiscal 2024 was principally attributable to ongoing management's efforts on improving profitability, as well as the $13.2 million intangible impairment during 2023.</li>
<li>At September 30, 2024, we had working capital of approximately $1.1 million and cash on hand of approximately $2.4 million (which includes $4.7 million of accrued Series A dividend payments) as compared to working capital of approximately $3.4 million and cash on hand of approximately $1.8 million (which includes $0.67 million of accrued Series A dividend payments) at September 30, 2023.</li>
<li>We reported direct to consumer (DTC) net sales of $15.7 million or 80.4% of total net sales in fiscal 2024, a decrease of $3.9 million, or 19.9% from fiscal 2023.</li>
<li>As of the filing date of our annual report, the majority of our Notes have been converted and the balance of the Notes totaled approximately $0.36 million. When factoring in our cash balance of $2.4 million at the end of September 30, 2024 and ongoing cash consumption rate, management believe the Company has a strong liquidity position going into calendar 2025.</li>
</ul>
Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), cbdMD is reporting that its audited consolidated financial statements for the fiscal year ended September 30, 2024, included in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2024, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to cbdMD's ability to continue as a going concern. This announcement does not represent any change or amendment to cbdMD's financial statements or to its Annual Report on Form 10-K for the fiscal year ended September 30, 2024.
We will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss our September 30, 2024, fourth quarter and full fiscal year financial results and business progress.

YCBD

cbdMD FY24 EPS $(1.79) Up From $(13.32) YoY; Revenue $19.48M Down From $24.16M YoY

WIIM

Worthington Steel shares are trading lower. The company reported Q2 financial results.

The securities sale is part of the Company's strategy to proactively maximize the balance sheet with the goal of driving future earnings.&nbsp;
The securities sold represented approximately 20% of the Company's AFS portfolio and resulted in an after-tax loss of approximately $5 million that will be recorded in the fourth quarter of 2024. Proceeds from the sale will be redeployed over time into higher yielding securities.

NBHC

National Bank Holdings Reports Sale Of $130M Of Available-For-Sale Investment Securities On The Open Market

Steelcase shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) reported quarterly earnings of $0.19 per share. This is a 72.73 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $739.00 million which beat the analyst consensus estimate of $719.45 million by 2.72 percent. This is a 8.54 percent decrease over sales of $808.00 million the same period last year.

Earnings Beats

Worthington Steel Q2 Adj $0.19 Up From $0.11 YoY, Sales $739.00M Beat $719.45M Estimate

Guidance

Steelcase Sees Q4 Adj. EPS $0.20-$0.24 Vs $0.22 Est.; Revenue $770M-$795M Vs $834.560M Est.

Contracts

Trane Technologies Announced It Has Signed A Definitive Agreement To Aquire BrainBox AI; Terms Not Disclosed

Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.22 by 36.36 percent. The company reported quarterly sales of $794.900 million which missed the analyst consensus estimate of $800.580 million by 0.71 percent. This is a 2.19 percent increase over sales of $777.900 million the same period last year.

Earnings Misses

Steelcase Q3 2025 Adj. EPS $0.30 Beats $0.22 Estimate, Sales $794.900M Miss $800.580M Estimate

Third Quarter and Fiscal 2025 Outlook The table below presents our expectations for third quarter and selected full year fiscal 2025 financial operating results:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Q3 FY2025</td>
<td colspan="1" rowspan="1">Full Year FY25</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales</td>
<td colspan="1" rowspan="1">$903 million to $943 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross margin %</td>
<td colspan="1" rowspan="1">38.1% to 39.1%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted operating expenses&#x2A;</td>
<td colspan="1" rowspan="1">$293 million to $303 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest and other expense, net</td>
<td colspan="1" rowspan="1">$16.7 million to $17.7 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted effective tax rate&#x2A;</td>
<td colspan="1" rowspan="1">21.5% to 23.5%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted earnings per share - diluted&#x2A;</td>
<td colspan="1" rowspan="1">$0.41 to $0.47</td>
<td colspan="1" rowspan="1">$2.11 to $2.17</td>
</tr>
<tr>
<td colspan="3" rowspan="1">&#x2A;Items indicated represent Non-GAAP measures. The Q3 FY2025 outlook excludes an expected $6 million in operating expense charges related to amortization of Knoll purchased intangibles and the related tax and earnings per share impact.</td>
</tr>
</tbody>
</table>
</figure>
We are encouraged with both internal and external indicators that collectively support an expectation of improving demand trends in most of our markets.&nbsp; While we expect our fiscal third quarter to be impacted by typical seasonal softness in our Americas and International Contracts businesses as the calendar year comes to a close and by the timing of the Chinese New Year holiday, our full year guide reflects the improving demand trends. We narrowed our full year adjusted earnings per share range and modestly lowered the midpoint given the slower than expected macroeconomic improvements and lower than expected orders in the first half of the year. Our updated guidance continues to reflect full year sales and EPS growth over fiscal 2024.&nbsp;
Due to the timing dynamic of this year's holiday/cyber promotional period, we estimate approximately $12 million in Global Retail net sales shifted from our fiscal second quarter into our fiscal third quarter, as compared to the prior year.&nbsp; This is reflected in our third quarter guidance.

MillerKnoll Sees Q3 EPS $0.41-$0.47 Vs $0.56 Est.; Revenue $903M-$943M Vs $927.15M Est.

Biotech

General

IRIX

Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.

TC BioPharm (TCBP) announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treat...

TC Biopharm enters research pact with Dr. Carlos Maluquer de Motes

The company said, "TC BioPharm (TCBP) refuted a false claim made earlier this week on social media, stating there is absolutely no way the company ...

TC Biopharm refutes social media claim, remains compliant with Nasdaq rules

TC BioPharm (TCBP) announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex Grant Program. The G-ReX Grant Program, launc...

TC Biopharm awarded funding of $250,000 from G-Rex Grant Program

TC Biopharm (Holdings) Plc Sponsored ADR (TCBP) has released an update. TC Biopharm (Holdings) Plc has reported a challenging financial situation w...

TC Biopharm Faces Financial Strains Amid Rising Costs

16:08 EST TC Biopharm (TCBP) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaki...

TC Biopharm files $100M mixed securities shelf

TC BioPharm (TCBP) announced an update on the progression of the ACHIEVE UK Trial. As of this week, over half of the Cohort A patients in Stage One...

TC Biopharm provides quarterly update on ACHIEVE UK Trial

H.C. Wainwright lowered the firm's price target on TC Biopharm (TCBP) to $3 from $7 and keeps a Buy rating on the shares. The firm updated its mode...

TC Biopharm price target lowered to $3 from $7 at H.C. Wainwright

TC BioPharm (TCBP) announced a partnership with CareDx (CDNA) who will perform pharmacokinetic analysis using its AlloCellsolution in the ACHIEVE c...

TC Biopharm announces partnership with CareDx

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm (Holdings) plc has announced a General Meeting sche...

TC BioPharm Announces Key Shareholder Meeting

The latest announcement is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm (Holdings) Plc has filed a prospectus supplem...

TC BioPharm Advances Strategic Financial Initiative with New ADS Offering

CDNA

TCBP

Press Releases

TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening

TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic

Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

Shares of This Biotech Surge Following Collaboration Announcement For Monkeypox Research

Social Media

TCBP Responds to False Social Media Claim

TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements

TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend

CRDL

CYCC

GNPX

PRSO

TSX:CRDL

Aditxt

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

Anitra

Bionomics Limited - American Depository Shares

Bionomics

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Carmell

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Oragenics

Onconetix

Palisade Bio

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Comments

TC BioPharm (Holdings)

Actualités

Dernières nouvelles pour TC BioPharm (Holdings) (NASDAQ:TCBP) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL